Equities analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to announce earnings of ($0.72) per share for the current quarter, Zacks reports. Three analysts have provided estimates for Paratek Pharmaceuticals’ earnings. The highest EPS estimate is ($0.56) and the lowest is ($0.88). Paratek Pharmaceuticals posted earnings per share of ($1.16) during the same quarter last year, which suggests a positive year over year growth rate of 37.9%. The company is expected to issue its next quarterly earnings report on Thursday, March 1st.

On average, analysts expect that Paratek Pharmaceuticals will report full-year earnings of ($3.32) per share for the current financial year, with EPS estimates ranging from ($3.78) to ($3.05). For the next year, analysts forecast that the business will report earnings of ($3.33) per share, with EPS estimates ranging from ($4.43) to ($2.51). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Paratek Pharmaceuticals.

PRTK has been the subject of several research analyst reports. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 2nd. Guggenheim initiated coverage on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 target price for the company. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $40.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can bought a new stake in shares of Paratek Pharmaceuticals in the 3rd quarter worth about $104,000. SG Americas Securities LLC bought a new stake in shares of Paratek Pharmaceuticals during the 3rd quarter valued at about $123,000. Legal & General Group Plc grew its position in shares of Paratek Pharmaceuticals by 13.3% during the 2nd quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock valued at $144,000 after buying an additional 687 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Paratek Pharmaceuticals during the 2nd quarter valued at about $172,000. Finally, Citigroup Inc. grew its position in shares of Paratek Pharmaceuticals by 19,470.0% during the 2nd quarter. Citigroup Inc. now owns 7,828 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 7,788 shares during the last quarter. 84.30% of the stock is owned by institutional investors.

Paratek Pharmaceuticals (PRTK) traded down $0.08 on Friday, hitting $18.77. 264,161 shares of the stock traded hands, compared to its average volume of 338,200. The company has a market cap of $526.69, a P/E ratio of -5.03 and a beta of 0.70. Paratek Pharmaceuticals has a one year low of $13.95 and a one year high of $29.00. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53.

ILLEGAL ACTIVITY WARNING: “-$0.72 Earnings Per Share Expected for Paratek Pharmaceuticals Inc (PRTK) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/0-72-earnings-per-share-expected-for-paratek-pharmaceuticals-inc-prtk-this-quarter.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Get a free copy of the Zacks research report on Paratek Pharmaceuticals (PRTK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.